

# Montenegro

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–<0.01)	0.41 (0.38–0.44)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.05 (0.01–0.1)
Incidence (includes HIV+TB)	0.13 (0.084–0.19)	21 (13–30)
Incidence (HIV+TB only)	<0.01 (<0.01–<0.01)	0.17 (0.11–0.25)
Incidence (MDR/RR-TB)**	<0.01 (0–<0.01)	0.5 (0–1.2)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0–14 years	> 14 years	Total
Females	0 (0–<0.01)	0.036 (0.01–0.063)	0.036 (<0.01–0.066)
Males	0.01 (<0.01–0.014)	0.084 (0.059–0.11)	0.094 (0.065–0.12)
Total	0.01 (<0.01–0.013)	0.12 (0.093–0.15)	0.13 (0.084–0.19)

## TB case notifications, 2015

Total cases notified	80
Total new and relapse	80
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	91%
- % pulmonary	96%
- % bacteriologically confirmed among pulmonary	74%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	62% (43–95)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.02 (0.02–0.04)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	1	1%
- on antiretroviral therapy	1	100%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			1 (0–4)
Estimated % of TB cases with MDR/RR-TB	1.9% (0.05–10)	0% (0–60)	
% notified tested for rifampicin resistance	71%	80%	57
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 1, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 1, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	89%	113
Previously treated cases, excluding relapse, registered in 2014		0
HIV-positive TB cases, all types, registered in 2014		0
MDR/RR-TB cases started on second-line treatment in 2013		0
XDR-TB cases started on second-line treatment in 2013		0

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

## TB financing, 2016

National TB budget (US\$ millions)

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015




## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically